Biomarin Pharmaceutical Q3 2024 Adj EPS $0.91 Beats $0.52 Estimate, Sales $745.74M Beat $700.14M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biomarin Pharmaceutical reported strong Q3 2024 results, with earnings per share of $0.91, significantly surpassing the expected $0.52. Sales also exceeded expectations, reaching $745.74 million, a 28.28% increase from the previous year.
October 29, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biomarin Pharmaceutical's Q3 2024 earnings and sales significantly exceeded analyst expectations, with EPS at $0.91 versus the expected $0.52 and sales at $745.74 million versus the expected $700.14 million.
The significant beat on both EPS and sales suggests strong operational performance and potential positive investor sentiment, likely leading to a short-term stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100